Research and Markets: New Strategies in Pharmaceutical Academic-Industry Collaborations Revealed

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/d981ae/new_strategies_in) has
announced the addition of Decision Resources, Inc.'s new report "New Strategies
in Pharmaceutical Academic-Industry Collaborations" to their offering.

Major pharmaceutical companies are showing increased interest in directly
sponsoring academic research to access innovation and fill dwindling pipelines.
Recent agreements involve higher levels of collaboration and funding, are
broader in scope, and focus on more-basic research than previously. This
increased collaboration among scientists performing basic research, clinical
researchers, and drug developers will accelerate the shift to translational
medicine and has the potential to yield great benefits to patients and society.

Questions Answered in This Report

* Pharmaceutical companies have recently formed numerous collaborations with
large research institutions. What factors are driving this interest? What are
the key features of recent collaborative agreements? How does each organization
benefit from these arrangements?
* The environment of academic technology transfer to industry is changing. What
impact has the Bayh-Dole Act had on technology transfer? How do academic
institutions manage academic industry relationships? Which institutions are
leading in innovation and commercialization of technology?
* Drug developers are experimenting with different approaches to
academic-industry relations. Which key collaborations illustrate these new
approaches? What strategic interests of the pharmaceutical industry do these
agreements serve? How will universities and companies measure success?
* Relationships between academia and industry present special challenges. How do
the missions and goals of academia and industry differ? What conflicts can arise
with respect to industry funding of academic researchers? How can institutions
and companies manage these differences?

Scope

* Factors in academic-industry collaborations: historical relationships,
dwindling pharmaceutical pipelines, diminishing federal funding for academia.
* Technology transfer: impact of Bayh-Dole, tech transfer offices, inventions
and innovation, challenges in academic-industry relationships.
* New approaches in academic-industry relationships: close-collaboration,
broad-scope, early-stage research.
* Translational medicine: theme of collaborations, goals, motivations.
* Drug discovery centers: academic centers for dug discovery, industry discovery
centers, pharmaceutical incubators.
* Notable collaborators: AstraZeneca, Centocor, GlaxoSmithKline, Janssen
Pharmaceutica, Merck, Novartis, Pfizer; Columbia University Medical Center,
Harvard Medical School, Harvard Stem Cell Institute, Immune Disease Institute,
MIT, University of California, San Francisco, University of Michigan, Vanderbilt
University, Washington University.

Key Topics Covered:

* Executive Summary
* Introduction to Academic-Industry Collaborations
* Impact of Bayh-Dole on Technology Transfer to Industry
* New Approaches in Academic-Industry Collaborations
* Academic and Industry Centers for Drug Discovery
* Academic-Industry Collaborations of Note
* Outlook for Academic-Industry Collaborations
* Tables
* Figures

Companies Mentioned:

For the complete list of 61 companies/academic institutes that feature in this
report, click the link below.

http://www.researchandmarkets.com/research/d981ae/new_strategies_in

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716

Copyright Business Wire 2009